Aerie Pharmaceuticals Inc. (AERI) PT Raised to $55.00
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) had its price objective raised by equities researchers at Stifel Nicolaus to $55.00 in a note issued to investors on Thursday. Stifel Nicolaus’ price objective suggests a potential upside of 40.09% from the stock’s current price.
Other analysts have also recently issued research reports about the company. Brean Capital reiterated a “buy” rating and set a $63.00 target price on shares of Aerie Pharmaceuticals in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $52.00 target price (up previously from $45.00) on shares of Aerie Pharmaceuticals in a report on Thursday, September 15th. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Tuesday, July 12th. Royal Bank Of Canada boosted their target price on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, September 15th. Finally, HC Wainwright began coverage on Aerie Pharmaceuticals in a report on Tuesday, September 20th. They set a “buy” rating and a $66.00 target price for the company. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $51.40.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at 39.26 on Thursday. The firm has a 50-day moving average of $27.34 and a 200 day moving average of $19.13. The stock’s market capitalization is $1.10 billion. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $41.72.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.02. On average, analysts anticipate that Aerie Pharmaceuticals will post ($2.80) EPS for the current year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the stock in a transaction dated Friday, July 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.77% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Spark Investment Management LLC bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth approximately $1,968,000. Geode Capital Management LLC increased its position in shares of Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock worth $1,961,000 after buying an additional 925 shares during the last quarter. Kennedy Capital Management Inc. increased its position in shares of Aerie Pharmaceuticals by 14.3% in the first quarter. Kennedy Capital Management Inc. now owns 54,296 shares of the company’s stock worth $660,000 after buying an additional 6,787 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Aerie Pharmaceuticals by 24.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,025,000 shares of the company’s stock worth $24,624,000 after buying an additional 400,000 shares during the last quarter. Finally, A.R.T. Advisors LLC increased its position in shares of Aerie Pharmaceuticals by 126.7% in the first quarter. A.R.T. Advisors LLC now owns 172,032 shares of the company’s stock worth $2,091,000 after buying an additional 96,145 shares during the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.